Brian Helfand, MD, PhD

GU Oncology Now

Brian Helfand, MD, PhD, NorthShore University HealthSystem, details the intended purpose of 18F-rhPSMA-7.3, how it compares to other PSMA PET radiopharmaceuticals or conventional imaging modalities, its ability to detect really distant disease, and how this is likely to impact treatment and patient management in the future.In May 2023, 18F-rhPSMA-7.3 became the <a href="https://guoncologynow.com/post/posluma-becomes-first-and-only-fda-approved-psma-targeted-pet-imaging-agent" target="_blank" rel="noopener">first FDA-approved radiohybrid PSMA-targeted PET imaging agent</a>. 18F-rhPSMA-7.3 is an optimized diagnostic imaging agent for the PET detection of PSMA-positive lesions in patients with prostate cancer with suspected metastasis or suspected recurrence based on elevated serum PSA level or who are candidates for initial definite therapy.

Dr. Brian Helfand on the SPOTLIGHT Study: Recurrent Prostate Cancer Detection With 18F-rhPSMA-7.3

Radioligand therapy prostate-specific membrane antigen

Dr. Brian Helfand details the intended purpose of 18F-rhPSMA-7.3, as well as how it compares to other PSMA PET RLTs or conventional imaging modalities.

Dr. Brian Helfand on the SPOTLIGHT Study: 18F-rhPSMA-7.3

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe